Aligos Therapeutics, Inc.(ALGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALGS Aligos Therapeutics, Inc.

Market Closed 06-26 16:00:00 EDT

5.57

+0.07

+1.27%

盘后5.57

+0.000.00%

19:52 EDT

High5.74	Low5.30	Vol54.41K
Open5.34	D1 Closing5.50	Amplitude7.91%
Mkt Cap34.47M	Tradable Cap20.28M	Total Shares6.19M
T/O300.53K	T/O Rate1.49%	Tradable Shares3.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALGS","market":"US","secType":"STK","nameCN":"Aligos Therapeutics, Inc.","latestPrice":5.57,"timestamp":1782504000000,"preClose":5.5,"halted":0,"volume":54406,"hourTrading":{"tag":"盘后","latestPrice":5.57,"preClose":5.57,"latestTime":"19:52 EDT","volume":30,"amount":166.94,"timestamp":1782517939273,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01272727272727278,"floatShares":3641200,"shares":6188200,"eps":-8.698447,"marketStatus":"Market Closed","change":0.07,"latestTime":"06-26 16:00:00 EDT","open":5.34,"high":5.735,"low":5.3,"amount":300526.5352936,"amplitude":0.079091,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.698447,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":5.5,"preHourTrading":{"tag":"盘前","latestPrice":5.13,"preClose":5.5,"latestTime":"08:25 EDT","volume":324,"amount":1761.2889480000001,"timestamp":1782476758175,"change":-0.37,"changeRate":-0.067273,"amplitude":0.067273},"postHourTrading":{"tag":"盘后","latestPrice":5.57,"preClose":5.57,"latestTime":"19:52 EDT","volume":30,"amount":166.94,"timestamp":1782517939273,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.906715,"impliedVol":0.1576,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ALGS","defaultTab":"news","newsList":[{"id":"2646600713","title":"Aligos Therapeutics Shareholders Approve Directors and Governance Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2646600713","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646600713?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:37","pubTimestamp":1782506269,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics ( ($ALGS) ) has provided an announcement. On June 25, 2026, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aligos-therapeutics-shareholders-approve-directors-and-governance-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aligos-therapeutics-shareholders-approve-directors-and-governance-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","ALGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646367024","title":"Aligos Therapeutics Shareholders Approve ESPP Share Reserve Increase, Remove Evergreen Provision","url":"https://stock-news.laohu8.com/highlight/detail?id=2646367024","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646367024?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:03","pubTimestamp":1782504187,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics shareholders approve ESPP share reserve increase, remove evergreen provisionAligos Therapeutics held its annual shareholder meeting on June 25, 2026.Shareholders adopted an amendme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL50sjCm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641124933","title":"Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2641124933","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641124933?lang=en_us&edition=fundamental","pubTime":"2026-06-06 21:06","pubTimestamp":1780751214,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-algs/aligos-therapeutics/news/heres-why-were-a-bit-worried-about-aligos-therapeutics-nasda-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-algs/aligos-therapeutics/news/heres-why-were-a-bit-worried-about-aligos-therapeutics-nasda-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JEPQ","QQQJ","NVIW.SI","QYLG","PSQ","QQQ","BK4505","NDX","QID","MNQmain","QLD","BK4139","NQmain","TQQY","ALGS","GPIQ","QQQA","TECS","IYW","QQQE","QDTE","FTEC","ONEQ","TQQQ",".IXIC","QQQM","QQQY","SQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640761950","title":"Analysts Are Bullish on Top Healthcare Stocks: Aligos Therapeutics (ALGS), Jade Biosciences (JBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640761950","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640761950?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:30","pubTimestamp":1780324206,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aligos Therapeutics (ALGS) and Jade Biosciences (JBI...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aligos-therapeutics-algs-jade-biosciences-jbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aligos-therapeutics-algs-jade-biosciences-jbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALGS","BK4505","JBIO","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639690179","title":"Aligos Therapeutics Initiated at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690179","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639690179?lang=en_us&edition=fundamental","pubTime":"2026-05-29 01:28","pubTimestamp":1779989280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALGS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2026 13:28 ET (17:28 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALGS","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638694868","title":"Analysts’ Top Healthcare Picks: Aligos Therapeutics (ALGS), Equillium (EQ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638694868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638694868?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:40","pubTimestamp":1779979208,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aligos Therapeutics (ALGS) and Equillium (EQ) with b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-aligos-therapeutics-algs-equillium-eq-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-aligos-therapeutics-algs-equillium-eq-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LABU","BK4505","EQ","BK4568","BK4137","ALGS","BK4139","LU0128526141.USD","BK4588","HCSG","BK4585","BK4581","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638681699","title":"Aligos Therapeutics initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2638681699","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638681699?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:28","pubTimestamp":1779974896,"startTime":"0","endTime":"0","summary":"Lake Street analyst Daniel Brims initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $45 price target based on the market opport...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-initiated-with-a-buy-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-initiated-with-a-buy-at-lake-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698441","title":"Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698441","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698441?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:04","pubTimestamp":1779969888,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (ALGS) has an average rating of Buy and mean price target of $56.29, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638505872","title":"Aligos Therapeutics presents data at EASL congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2638505872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638505872?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:15","pubTimestamp":1779873309,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (ALGS) announced data from ten presentations at the European Association for the Study of the Liver, or EASL, Congress 2026, be...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-presents-data-at-easl-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-presents-data-at-easl-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","ALGS","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638571169","title":"Aligos says Phase 1 follow-up data for pevifoscorvir sodium suggest reduction in HBV cccDNA reservoir","url":"https://stock-news.laohu8.com/highlight/detail?id=2638571169","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638571169?lang=en_us&edition=fundamental","pubTime":"2026-05-27 14:31","pubTimestamp":1779863461,"startTime":"0","endTime":"0","summary":"Aligos flagged positive Phase 1 follow-up results for pevifoscorvir sodium in chronic hepatitis B, already presented at the EASL Congress 2026.Post-treatment follow-up suggested antiviral effects persisted beyond dosing, supporting the drug’s strategy to shrink the viral reservoir.Separate data indicated a meaningful share of treated patients could become eligible for add-on functional-cure regimens that include antisense therapy.Preclinical combination work showed additive-to-synergistic activity for pevifoscorvir sodium with the ALG-170675 antisense program, supporting a multi-drug regimen approach.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL9hDBh9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALGS","BK4588","LU2210149790.SGD","LU2095319765.USD","BK4585","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","BK4505","NDAQ","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638571480","title":"Aligos Therapeutics Presents Positive Data at the EASL Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638571480","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638571480?lang=en_us&edition=fundamental","pubTime":"2026-05-27 14:30","pubTimestamp":1779863400,"startTime":"0","endTime":"0","summary":"Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO progra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301633/0/en/Aligos-Therapeutics-Presents-Positive-Data-at-the-EASL-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4141","BK4505","BK4585","ALGS","NA","BK4200","ASO","BK4528","BK4588","BK4233","BK4561","BK4205","UK","HDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637315671","title":"H.C. Wainwright Remains a Buy on Aligos Therapeutics (ALGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637315671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637315671?lang=en_us&edition=fundamental","pubTime":"2026-05-22 18:35","pubTimestamp":1779446130,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Aligos Therapeutics today and set a price target of $50.00. Trucchio covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-aligos-therapeutics-algs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-aligos-therapeutics-algs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALGS","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637599332","title":"Aligos Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2637599332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637599332?lang=en_us&edition=fundamental","pubTime":"2026-05-21 22:24","pubTimestamp":1779373440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALGS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 10:24 ET (14:24 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637387582","title":"Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2637387582","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637387582?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:39","pubTimestamp":1779359950,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Aligos Therapeutics (ALGS) with an Overweight rating and $20 price target Published first on TheFly – the u...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aligos-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635027209","title":"Aligos presents EASL data on pevifoscorvir sodium Phase 2 HBV dose selection","url":"https://stock-news.laohu8.com/highlight/detail?id=2635027209","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635027209?lang=en_us&edition=fundamental","pubTime":"2026-05-13 14:14","pubTimestamp":1778652891,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics outlined upcoming clinical and preclinical data disclosures at EASL Congress 2026 in Barcelona, with posters scheduled for May 27-30.Key clinical readouts will cover pevifoscorvir sodium monotherapy in chronic hepatitis B, highlighting sustained reductions in viral antigens during follow-up and broad antiviral activity across patient subgroups.Additional presentations will address dose-selection support work for pevifoscorvir sodium, aiming to inform next-stage development decisions.Pipeline updates will also include preclinical combination activity for an HBV antisense oligonucleotide program, along with earlier research in hepatitis delta and an oral PD-1/PD-L1 inhibitor concept for HBV and liver cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLykB0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014013.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","BK4505","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","BK4588","LU0314104364.USD","BK4112","SG9999014021.USD","SG9999014005.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4139","ALGS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635327225","title":"Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635327225","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635327225?lang=en_us&edition=fundamental","pubTime":"2026-05-13 14:05","pubTimestamp":1778652300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May  13, 2026  (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293668/0/en/Aligos-Therapeutics-Announces-Ten-Abstracts-Accepted-for-Presentation-at-the-EASL-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","BK4139","ASO","BK4561","ALGS","BK4505","BK4205","UK","BK4528","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634020034","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2634020034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634020034?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:00","pubTimestamp":1778493600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·ATL Braves C                                   1Q      (.78)   8:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","B","BETA","APC","CRCL","CLLS","AEYE","CEG","CVRX","ARMK","ACH","ACHV","ABOS","BODI","CHRS","BRCB","ABCL","CLSK","ALLT","CDRE","CINT","COOK","BATRK","APEI","ACXP","BTAI","ARVN","AGNT","AMBQ","ACM","DCGO","CEVA","BALY","CGBD","BCAX","ASTS","ACET","BATRA","BGS","BIOA","ATRO","BLNK","CERT","ANDG","BCSF","CBLL","AMTM","AIP","ALGS","ASRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171120","title":"Aligos Therapeutics Q1 EPS $(2.21) Beats $(2.28) Estimate, Sales $2.830M Beat $500.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171120","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171120?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:20","pubTimestamp":1778185210,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.21) per share which beat the analyst consensus estimate of $(2.28) by 3.07 percent. This is a 4.74 percent decrease over losses of $(2.11) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52390135/aligos-therapeutics-q1-eps-2-21-beats-2-28-estimate-sales-2-830m-beat-500-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aligos Therapeutics Q1 EPS $(2.21) Beats $(2.28) Estimate, Sales $2.830M Beat $500.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633761871","title":"Aligos Therapeutics Q1 Operating Expenses USD 29.759 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633761871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633761871?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184312,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX4C2DFB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","ALGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633927396","title":"Aligos Therapeutics Inc  expected to post a loss of $2.22 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633927396","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633927396?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:14","pubTimestamp":1778015646,"startTime":"0","endTime":"0","summary":"Aligos Therapeutics Inc  expected to post a loss of $2.22 a share - Earnings Preview Aligos Therapeutics Inc ALGS.OQ ALGS.O is expected to  show a rise in quarterly revenue when it reports  results on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I3I0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALGS","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aligos.com","stockEarnings":[{"period":"1week","weight":0.0549},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.1637},{"period":"6month","weight":-0.4491},{"period":"1year","weight":-0.2199},{"period":"ytd","weight":-0.4024}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.020655},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.084797},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.197646},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.12162},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.029634},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.089699},{"month":7,"riseRate":0.6,"avgChangeRate":0.030308},{"month":8,"riseRate":0.6,"avgChangeRate":0.114051},{"month":9,"riseRate":0,"avgChangeRate":-0.14617},{"month":10,"riseRate":0.4,"avgChangeRate":-0.048799},{"month":11,"riseRate":0.666667,"avgChangeRate":0.350449},{"month":12,"riseRate":0.333333,"avgChangeRate":0.114782}],"exchange":"NASDAQ","name":"Aligos Therapeutics, Inc.","nameEN":"Aligos Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aligos Therapeutics, Inc.(ALGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aligos Therapeutics, Inc.(ALGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aligos Therapeutics, Inc.,ALGS,Aligos Therapeutics, Inc.股票,Aligos Therapeutics, Inc.股票老虎,Aligos Therapeutics, Inc.股票老虎国际,Aligos Therapeutics, Inc.行情,Aligos Therapeutics, Inc.股票行情,Aligos Therapeutics, Inc.股价,Aligos Therapeutics, Inc.股市,Aligos Therapeutics, Inc.股票价格,Aligos Therapeutics, Inc.股票交易,Aligos Therapeutics, Inc.股票购买,Aligos Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aligos Therapeutics, Inc.(ALGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aligos Therapeutics, Inc.(ALGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}